Mr. James Passin is Fund Manager at FGS Advisors, LLC, an affiliate of New York-based Firebird Management LLC. He has 19 years of experience as a professional investor, a deep experience of financing and developing venture-stage companies, and directed and managed over $155 million of equity and debt investment into biotech companies including Avax Technologies, Inc., one of the world's first cellular immunotherapeutic vaccine companies. He is a director of several public companies, including Blockchain Holdings, Ltd. (CSE: BSX), Sharyn Gol JSC (MSE: SHG), and BDSec JSC (MSE: BDS), is a Chartered Market Technician and member of the CMT Association.
Mr. Kenneth Kovan is Managing Principal and owner of BinghamHill Ventures, a lifesciences advisory practice. He has over 20 years experience leading early-stage biotech companies, in university medical research commercialization, and with global pharmaceutical companies. He is an experienced biotechnology CEO, for-profit and non-profit board member, corporate adviser, a founder of several biotech companies including cancer immunotherapeutic vaccine company AVAX Technologies Inc. as well as a venture developing small molecule therapeutics targeting hsp70, and has been Director of Global New Product Development & Strategic Marketing for a Fortune 500 global pharmaceutical corporation. He has a broad international business background, having worked extensively in Latin American and Asia/Pacific markets, as well as resided in Europe for many years. Mr. Kovan holds a US Patent for a novel synergistic drug combination.
Dr. David Berd is a medical oncologist with a lifelong record of clinical research in medical oncology and cancer immunotherapy. He cofounded cancer immunotherapy company AVAX Technologies, is the inventor of the cancer vaccines MVax™ and OVax™, and served as Chief Medical Officer 2005-2008. As National Director for Immunotherapy at Cancer Treatment Centers of America, Dr. Berd investigated the application of the AC vaccine to ovarian cancer. Previously, Dr. Berd was Professor of Medicine at Thomas Jefferson University, where for 20 years he conducted clinical research on melanoma immunotherapy. He also spent nine years as a research physician at Fox Chase Cancer Center. Over the course of his career, Dr. Berd has published more than 85 original papers in numerous medical journals alongside dozens of editorials, reviews and abstracts. He has ten issued patents dealing with cancer vaccines. Throughout his career, he has participated in national and international conferences on melanoma and cancer immunotherapy. Dr. Berd received his BS from Pennsylvania State University and his MD from Jefferson Medical College of Thomas Jefferson University.